Sankyo Selected Evotec as Assay Development and Screening
News Apr 28, 2006
Evotec will apply their skills and proprietary technologies in assay development and ultra-high throughput screening (uHTS) to identify biologically active molecules from its corporate library that interact with disease targets selected by Sankyo.
Compounds identified in screening will be further characterised and prioritised by Evotec for progression into Sankyo’s subsequent lead optimisation programmes.
Dr Mark Ashton, Executive Vice President Business Development Services at Evotec, said, "We are delighted and proud that Sankyo, one of the largest pharmaceutical companies in Japan, has selected us for these important drug finding projects."
"We enjoyed the constructive and open discussions during the planning phase of this collaboration. These projects represent another important milestone in strengthening our collaborative relationships with pharmaceutical companies in Japan."
"This project is an important extension of our lead discovery activities, and we appreciate Evotec's technological capabilities as well as the commitment to the project."
"We already enjoyed the atmosphere of mutual respect and believe that this collaboration will be successful," commented Dr Hideyuki Haruyama, Corporate Officer and General Manager, Research Institute at Sankyo.
Old age is the greatest risk factor for many diseases, including Alzheimer's disease (AD) and cancer. Geroprotectors are a recently identified class of anti-aging compounds. New research has now identified a unique subclass of these compounds, dubbed geroneuroprotectors (GNPs), which are AD drug candidates and slow the aging process in mice.READ MORE